Standards; Pharmaceutical/API Drug Impurities/Metabolites;
应用:
LY 2922470, has demonstrated potent, efficacious and durable dose dependent reduction in glucose levels along with significant increases in insulin and GLP-1 secretion during preclinical testing. It’s a novel, potent and Selective GPR40 Agonists for the treatment of type 2 Diabetes Mellitus.
您的位置：
